IL131042D0 - Arylsulfonylamino hydroxamic acid derivatives - Google Patents

Arylsulfonylamino hydroxamic acid derivatives

Info

Publication number
IL131042D0
IL131042D0 IL13014298A IL13014298A IL131042D0 IL 131042 D0 IL131042 D0 IL 131042D0 IL 13014298 A IL13014298 A IL 13014298A IL 13014298 A IL13014298 A IL 13014298A IL 131042 D0 IL131042 D0 IL 131042D0
Authority
IL
Israel
Prior art keywords
acid derivatives
hydroxamic acid
arylsulfonylamino hydroxamic
arylsulfonylamino
derivatives
Prior art date
Application number
IL13014298A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US3685797P priority Critical
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to PCT/IB1998/000023 priority patent/WO1998033768A1/en
Publication of IL131042D0 publication Critical patent/IL131042D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
IL13014298A 1997-02-03 1998-01-12 Arylsulfonylamino hydroxamic acid derivatives IL131042D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US3685797P true 1997-02-03 1997-02-03
PCT/IB1998/000023 WO1998033768A1 (en) 1997-02-03 1998-01-12 Arylsulfonylamino hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
IL131042D0 true IL131042D0 (en) 2001-01-28

Family

ID=21891041

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13104298A IL131042A (en) 1997-02-03 1998-01-12 Arylsulfonylamino hydroxamic acid derivatives and pharmaceutical compositions comprising them
IL13014298A IL131042D0 (en) 1997-02-03 1998-01-12 Arylsulfonylamino hydroxamic acid derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13104298A IL131042A (en) 1997-02-03 1998-01-12 Arylsulfonylamino hydroxamic acid derivatives and pharmaceutical compositions comprising them

Country Status (43)

Country Link
US (1) US6303636B1 (en)
EP (1) EP0977733B1 (en)
JP (1) JP3765584B2 (en)
KR (1) KR100317146B1 (en)
CN (1) CN1113862C (en)
AP (1) AP826A (en)
AR (1) AR011101A1 (en)
AT (1) AT248812T (en)
AU (1) AU721748B2 (en)
BG (1) BG64308B1 (en)
BR (1) BR9807815A (en)
CA (1) CA2279276C (en)
CO (1) CO4920234A1 (en)
DE (1) DE69817801T2 (en)
DK (1) DK0977733T3 (en)
DZ (1) DZ2410A1 (en)
EA (1) EA002594B1 (en)
ES (1) ES2202796T3 (en)
GT (1) GT199800025A (en)
HK (1) HK1026203A1 (en)
HN (1) HN1998000011A (en)
HR (1) HRP980058B1 (en)
HU (1) HU0000852A2 (en)
ID (1) ID22799A (en)
IL (2) IL131042A (en)
IS (1) IS1950B (en)
MA (1) MA26471A1 (en)
MY (1) MY121754A (en)
NO (1) NO313631B1 (en)
NZ (1) NZ336840A (en)
OA (1) OA11081A (en)
PA (1) PA8445801A1 (en)
PE (1) PE57799A1 (en)
PL (1) PL335027A1 (en)
PT (1) PT977733E (en)
SK (1) SK283963B6 (en)
TN (1) TNSN98019A1 (en)
TR (1) TR199901849T2 (en)
TW (1) TW509668B (en)
UA (1) UA63935C2 (en)
UY (1) UY24866A1 (en)
WO (1) WO1998033768A1 (en)
ZA (1) ZA9800823B (en)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298617A1 (en) 1997-07-31 1999-02-11 Yetunde Olabisi Taiwo Acyclic metalloprotease inhibitors
PA8469601A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc Process for alkylating hindered sulfonamides
PA8469301A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedures for preparing hydroxamic acids.
GT199900044A (en) * 1998-04-10 2000-09-14 Methods for preparing phenoxyphenylsulfonyl halides.
PA8479201A1 (en) * 1998-08-12 2000-09-29 Pfizer Prod Inc Hydroxamic acid derivatives of hydroxy-pipecolate
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
EP1147085B1 (en) 1999-01-27 2005-11-16 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
JP2002538136A (en) 1999-03-03 2002-11-12 ザ プロクター アンド ギャンブル カンパニー Alkenyl and alkynyl containing metalloprotease inhibitor
TR200102524T2 (en) 1999-03-03 2002-02-21 The Procter & Gamble Company Dihetero substituted metalloprotease inhibitors.
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
AT245152T (en) 1999-03-31 2003-08-15 Pfizer Prod Inc Dioxocyclopentylhydroxamsäure
ES2208315T3 (en) 1999-05-28 2004-06-16 Pfizer Products Inc. Acid hydroxyamide 3- (arylsulfonamido) -tetrahydropyran-3-carboxylic.
HN2000000052A (en) * 1999-05-28 2001-02-02 Pfizer Prod Inc Acid hydroxyamide 3- (arylsulfonylamino) -tetrahydrofuran-3-carboxylic.
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
IL138686D0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
PT1233948E (en) 1999-11-11 2009-04-16 Osi Pharm Inc Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
BR0109353A (en) * 2000-03-21 2003-04-08 Procter & Gamble Side chain containing heterocyclic metalloprotease inhibitors
JP2003528082A (en) 2000-03-21 2003-09-24 ザ プロクター アンド ギャンブル カンパニー Difluoride butyric acid inhibitor of metalloproteinase
CN1425004A (en) 2000-03-21 2003-06-18 宝洁公司 N-substituted metal proteinase inhibitor with heterocyclic side chain
AU9013101A (en) * 2000-09-29 2002-04-22 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2002045750A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Combination drugs
UY27087A1 (en) 2001-01-05 2002-06-20 Pfizer Antibodies against factor receptor insulin-like growth
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
JP2005507937A (en) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイションWyeth Holdings Corporation Allen arylsulfonamido hydroxamic acids as matrix metalloproteinases and tace inhibitors
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
EP1466899A4 (en) * 2001-12-27 2010-01-06 Dainippon Sumitomo Pharma Co Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
JP4502641B2 (en) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド Anti-cancer combinations and methods of use thereof
DE10206404A1 (en) * 2002-02-14 2003-08-28 Gruenenthal Gmbh Synthesis of substituted Sulfonylaminen
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
DOP2003000613A (en) 2002-03-13 2003-09-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors (n3 alkylated benzimidazole derivatives as mek inhibitors)
CA2489466A1 (en) 2002-06-14 2003-12-24 Pfizer Inc. Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
PL377713A1 (en) 2002-12-19 2006-02-06 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
US20060148839A1 (en) * 2003-02-11 2006-07-06 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
RS53118B (en) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaryl compounds as protein kinase inhibitors
BRPI0413876A (en) 2003-08-29 2006-10-24 Pfizer tienopiridin-phenylacetamides and derivatives thereof useful as antiangiogenic agents
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co Antibodies to m-csf
ES2355797T7 (en) 2003-11-19 2013-04-01 Array Biopharma, Inc. MEK heterocyclic inhibitors
AT473967T (en) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazole as gsk-3 inhibitors
ITFI20040174A1 (en) 2004-08-03 2004-11-03 Protera S R L Hydroxamic acid derivatives arilsolfonammidici to inhibitory action of metalloproteinases
WO2006021884A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
RU2414455C2 (en) 2005-05-18 2011-03-20 Астразенека Аб Heterocyclic mek inhibitors and methods of using thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2924418A1 (en) 2007-07-30 2009-02-05 Jean-Michel Vernier Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
ES2374450T3 (en) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Anti-bangeous response biological markers for kinner inhibitors of the growth factor receiver 1 similar to insulin.
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulfate salt
RU2008142598A (en) * 2006-03-29 2010-05-10 Новартис АГ (CH) Selective hydroxamate inhibitors of MMPs
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
CN101454004B (en) 2006-04-18 2013-12-04 阿迪亚生命科学公司 Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
EP2121620B1 (en) 2007-01-19 2015-06-17 Ardea Biosciences, Inc. Inhibitors of mek
BRPI0810411B1 (en) 2007-04-18 2019-09-10 Pfizer Prod Inc sulfonyl amide derivatives for the treatment of abnormal cell growth, its sos as well as pharmaceutical composition
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
AU2008259804B2 (en) * 2007-06-05 2013-04-18 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
CA2706571C (en) 2007-12-19 2012-11-27 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
NZ586575A (en) 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
CN102124009B (en) 2008-07-08 2014-07-23 因特利凯公司 Kinase inhibitors and methods of use
EP2334701A4 (en) 2008-10-16 2014-01-08 Univ Pittsburgh Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2393362B1 (en) 2009-02-05 2016-08-24 Immunogen, Inc. Novel benzodiazepine derivatives
CN102307875A (en) 2009-02-09 2012-01-04 苏伯俭股份有限公司 Pyrrolopyrimidinyl axl kinase inhibitors
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2411366B8 (en) 2009-03-27 2015-07-15 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
JP2013500991A (en) 2009-07-31 2013-01-10 オーエスアイ・ファーマシューティカルズ,エルエルシー mTOR inhibitor and angiogenesis inhibitor combination therapy
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
CA2814617C (en) 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
JP5889795B2 (en) 2009-11-05 2016-03-22 ライゼン・ファーマシューティカルズ・エスアー Novel kinase modulator
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
RS55487B1 (en) 2010-02-12 2017-04-28 Pfizer Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
ES2593256T3 (en) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulations
ES2695899T3 (en) 2010-06-16 2019-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Antibodies against endoplasmin and its use
FR2962649A1 (en) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Treatment of a pathology associated with excessive tnf effect by a benzene sulfonamide compound
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US9534000B2 (en) 2011-02-15 2017-01-03 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
ES2724801T3 (en) 2011-04-19 2019-09-16 Pfizer Combinations of anti-4-1BB antibodies and ADCC inducing antibodies for cancer treatment
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
LT2705029T (en) 2011-05-04 2019-02-11 Rhizen Pharmaceuticals S.A. Novel compounds as modulators of protein kinases
EP3415139A1 (en) 2011-06-14 2018-12-19 Hale Biopharma Ventures, Llc Administration of benzodiazepine
CN103946226A (en) 2011-07-19 2014-07-23 无限药品股份有限公司 Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2671748T3 (en) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2758402B9 (en) 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidine and purine derivatives
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
AU2011378675B2 (en) 2011-10-04 2017-10-05 Igem Therapeutics Limited IgE anti -HMW-MAA antibody
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
EP2817004B1 (en) 2012-02-22 2018-04-11 The Regents of The University of Colorado, A Body Corporate Bouvardin derivatives and therapeutic uses thereof
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
PL2890402T3 (en) 2012-08-31 2019-08-30 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP2914296B1 (en) 2012-11-01 2018-05-30 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014194254A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
CN105246482A (en) 2013-03-15 2016-01-13 因特利凯有限责任公司 Combination of kinase inhibitors and uses thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6473133B2 (en) 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Covalent inhibitor of KRASG12C
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
PT3052096T (en) 2013-10-03 2018-04-04 Kura Oncology Inc Inhibitors of erk and methods of use
SG11201602445SA (en) 2013-10-04 2016-04-28 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
WO2015054572A1 (en) 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105916853B (en) 2013-11-21 2018-07-27 辉瑞公司 2,6- substituted purin derivatives and its purposes in treating proliferative diseases
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
KR20160149256A (en) 2014-04-30 2016-12-27 화이자 인코포레이티드 Cycloalkyl-linked diheterocycle derivatives
SI3157916T1 (en) 2014-06-19 2019-05-31 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
TW201625305A (en) 2014-09-18 2016-07-16 Araxes Pharma Llc Combination therapy for the treatment of cancer
JP2017528498A (en) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Inhibitors of KRAS G12C mutant protein
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
JP2017537951A (en) 2014-12-18 2017-12-21 ファイザー・インク Pyrimidine and triazine derivatives and their use as AXL inhibitors
EA201792214A1 (en) 2015-04-10 2018-01-31 Араксис Фарма Ллк Compounds of substitute quinazoline
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356359A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US20180282307A1 (en) 2015-09-28 2018-10-04 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
WO2017087528A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EA201891304A1 (en) 2015-12-03 2019-01-31 Агиос Фармасьютикалс, Инк. MAT2A INHIBITORS FOR THE TREATMENT OF MTAP-null MALIGNANT TUMORS
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
AU2017212739A1 (en) 2016-01-27 2018-07-26 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
US20190135833A1 (en) 2016-06-08 2019-05-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20190276523A1 (en) 2016-09-02 2019-09-12 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
EP3362471A1 (en) 2016-12-19 2018-08-22 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
US20180177767A1 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140598A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190062314A1 (en) 2017-05-25 2019-02-28 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2018218070A2 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US20190077801A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019055909A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2268418A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company .alpha.-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
ES2190115T3 (en) * 1997-11-12 2003-07-16 Darwin Discovery Ltd Derivatives of hydroxamic and carboxylic acid with activity inhibiting MMP and TNF.
IL127496D0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
EP0952148B1 (en) * 1998-04-10 2004-05-12 Pfizer Products Inc. Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
PA8469501A1 (en) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas the acid (4-arylsulfonylamino) -tetrahydropyran-4-carboxylic acid

Also Published As

Publication number Publication date
AP9801191A0 (en) 1998-03-31
DK977733T3 (en)
IL131042A (en) 2004-07-25
DK0977733T3 (en) 2003-11-24
GT199800025A (en) 1999-07-24
PA8445801A1 (en) 2000-05-24
JP2000508350A (en) 2000-07-04
CO4920234A1 (en) 2000-05-29
AT248812T (en) 2003-09-15
CN1113862C (en) 2003-07-09
NZ336840A (en) 2001-01-26
DZ2410A1 (en) 2003-01-04
PE57799A1 (en) 1999-06-11
CA2279276C (en) 2005-09-13
DE69817801T2 (en) 2004-03-11
HU0000852A2 (en) 2001-05-28
AR011101A1 (en) 2000-08-02
US6303636B1 (en) 2001-10-16
JP3765584B2 (en) 2006-04-12
MY121754A (en) 2006-02-28
SK283963B6 (en) 2004-06-08
NO993730L (en) 1999-10-01
EA002594B1 (en) 2002-06-27
EP0977733A1 (en) 2000-02-09
CA2279276A1 (en) 1998-08-06
HRP980058A2 (en) 1998-12-31
UY24866A1 (en) 2000-09-29
IS1950B (en) 2004-10-13
SK101299A3 (en) 2002-04-04
ID22799A (en) 1999-12-09
ZA9800823B (en) 1999-08-02
CN1249743A (en) 2000-04-05
NO313631B1 (en) 2002-11-04
AU8191798A (en) 1998-08-25
TR199901849T2 (en) 2000-02-21
EP0977733B1 (en) 2003-09-03
AU721748B2 (en) 2000-07-13
EA199900604A1 (en) 2000-04-24
NO993730D0 (en) 1999-08-02
MA26471A1 (en) 2004-12-20
HN1998000011A (en) 1999-02-09
UA63935C2 (en) 2000-08-15
IS5129A (en) 1999-07-23
DE69817801D1 (en) 2003-10-09
AP826A (en) 2000-04-28
KR100317146B1 (en) 2001-12-22
HRP980058B1 (en) 2002-04-30
PL335027A1 (en) 2000-03-27
TNSN98019A1 (en) 2005-03-15
KR20000070721A (en) 2000-11-25
OA11081A (en) 2002-03-14
BR9807815A (en) 2000-03-08
HK1026203A1 (en) 2003-12-24
BG103616A (en) 2000-02-29
ES2202796T3 (en) 2004-04-01
TW509668B (en) 2002-11-11
PT977733E (en) 2003-12-31
WO1998033768A1 (en) 1998-08-06
BG64308B1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
DE69800640D1 (en) Pegylationsverfahren
DE69826254D1 (en) Modulare humerusprothese
DE69821950D1 (en) N-aroylphenylalaninderivate
DE69831868D1 (en) Antithrombosemittel
DE69827612D1 (en) Meatuspfropf
EG23729A (en) N-alkanoylphenylalanine derivatives
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
GB2314508B (en) Diamide-dicarboxylic acid microspheres
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
DE69531457D1 (en) Sulfonamide
DE69829667D1 (en) Hydrocyanierungsverfahren
DE69835201D1 (en) Neoglycoproteine
DE69837398D1 (en) Festphasenextrationsplatte
DE69804447D1 (en) Lithographisches system
DE69830051D1 (en) Endotrachealtubus
GB9825535D0 (en) Pyrometer-multimeter
IL132238D0 (en) Fungicidal trifluromethylalkylamino - triazolopyrimidines
GR3036714T3 (en) Fungicidal trifluorophenyl-triazolopyrimidines
HRP980439A2 (en) Fungicidal 2-methoxybenzophenones
PT813520E (en) Arylsulphonylamino hydroxamic acid derivatives
PL335027A1 (en) Derivatives of arylsulphonylamino hydroxamic acid
GB9702194D0 (en) Sulphonide derivatives
IL135836D0 (en) Substituted anilides
PL305701A1 (en) Pharmaceutical agent
HRP20000198A2 (en) Medicaments

Legal Events

Date Code Title Description
FF Patent granted